{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:18:50Z","timestamp":1790054330919,"version":"4.0.1"},"reference-count":128,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.repc.2022.02.014","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T16:31:47Z","timestamp":1678206707000},"page":"373-383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3045-2150","authenticated-orcid":false,"given":"Jorge","family":"Gon\u00e7alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4576-8147","authenticated-orcid":false,"given":"Catarina D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-7798","authenticated-orcid":false,"given":"Paula","family":"Fresco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-9595","authenticated-orcid":false,"given":"Fernando","family":"Fernandez-Llimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2022.02.014_bib0645","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.repc.2022.02.014_bib0650","doi-asserted-by":"crossref","first-page":"104927","DOI":"10.1016\/j.phrs.2020.104927","article-title":"ACEI\/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis","volume":"158","author":"Zhang","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.repc.2022.02.014_bib0655","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/HYPERTENSIONAHA.120.15572","article-title":"Decreased mortality of COVID-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis","volume":"76","author":"Guo","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.repc.2022.02.014_bib0660","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.amjcard.2020.05.038","article-title":"A meta-analysis of the relationship between renin-angiotensin-aldosterone system inhibitors and COVID-19","volume":"130","author":"Usman","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.repc.2022.02.014_bib0665","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/eurheartj\/ehaa433","article-title":"Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study","volume":"41","author":"Gao","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2022.02.014_bib0670","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/ehjcvp\/pvaa064","article-title":"A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers","volume":"7","author":"Grover","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.repc.2022.02.014_bib0675","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.dsx.2020.06.047","article-title":"The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis","volume":"14","author":"Pranata","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.repc.2022.02.014_bib0680","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/heartjnl-2020-317336","article-title":"Treatment with ACE inhibitors or ARBs and risk of severe\/lethal COVID-19: a meta-analysis","volume":"106","author":"Flacco","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.repc.2022.02.014_bib0685","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/ehjcvp\/pvaa074","article-title":"Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis","volume":"6","author":"Greco","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.repc.2022.02.014_bib0690","article-title":"Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: a rapid systematic review and meta-analysis","author":"Liu","year":"2020","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.repc.2022.02.014_bib0695","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/0036933020949219","article-title":"Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19","volume":"65","author":"Megaly","year":"2020","journal-title":"Scott Med J"},{"key":"10.1016\/j.repc.2022.02.014_bib0700","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11883-020-00880-6","article-title":"Effect of renin-angiotensin-aldosterone system inhibitors in patients with COVID-19: a systematic review and meta-analysis of 28,872 patients","volume":"22","author":"Baral","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.repc.2022.02.014_bib0705","first-page":"100627","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: systematic review and meta-analysis","volume":"31","author":"Caldeira","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.repc.2022.02.014_bib0710","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13098-020-00586-4","article-title":"Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis","volume":"12","author":"de Almeida-Pititto","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.repc.2022.02.014_bib0715","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11906-020-01101-w","article-title":"Renin-angiotensin system inhibitors and COVID-19: a systematic review and meta-analysis. Evidence for significant geographical disparities","volume":"22","author":"Patoulias","year":"2020","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.repc.2022.02.014_bib0720","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40256-020-00439-5","article-title":"Mortality and disease severity among COVID-19 patients receiving renin-angiotensin system inhibitors: a systematic review and meta-analysis","volume":"20","author":"Hasan","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.repc.2022.02.014_bib0725","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/14779072.2020.1826308","article-title":"Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis","volume":"18","author":"Lo","year":"2020","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.repc.2022.02.014_bib0730","doi-asserted-by":"crossref","first-page":"e00666","DOI":"10.1002\/prp2.666","article-title":"A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: what is the evidence so far?","volume":"8","author":"Kurdi","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.repc.2022.02.014_bib0735","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1093\/cid\/ciaa1592","article-title":"The effect of prior ACEI\/ARB treatment on COVID-19 susceptibility and outcome: a systematic review and meta-analysis","volume":"72","author":"Xu","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.repc.2022.02.014_bib0740","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.acvd.2020.09.002","article-title":"Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: a review and pooled analysis","volume":"113","author":"Kerneis","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.repc.2022.02.014_bib0745","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/jmv.26625","article-title":"The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: a systematic review and meta-analysis","volume":"93","author":"Wang","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.repc.2022.02.014_bib0750","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jjcc.2020.10.015","article-title":"Lack of association of antihypertensive drugs with the risk and severity of COVID-19: a meta-analysis","volume":"77","author":"Ren","year":"2021","journal-title":"J Cardiol"},{"key":"10.1016\/j.repc.2022.02.014_bib0755","doi-asserted-by":"crossref","first-page":"e001353","DOI":"10.1136\/openhrt-2020-001353","article-title":"Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis","volume":"7","author":"Ssentongo","year":"2020","journal-title":"Open Heart"},{"key":"10.1016\/j.repc.2022.02.014_bib0760","article-title":"Angiotensin converting enzyme inhibitors and angiotensin receptor blockers and mortality among COVID-19 patients: a systematic review and meta-analysis","author":"Kashour","year":"2020","journal-title":"Am J Ther"},{"key":"10.1016\/j.repc.2022.02.014_bib0765","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1111\/bcp.14660","article-title":"Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: systematic review and meta-analysis","volume":"87","author":"Chu","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.repc.2022.02.014_bib0770","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/jmv.26695","article-title":"Effects of renin-angiotensin-aldosterone system inhibitors on disease severity and mortality in patients with COVID-19: a meta-analysis","volume":"93","author":"Zhang","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.repc.2022.02.014_bib0775","doi-asserted-by":"crossref","first-page":"563","DOI":"10.11622\/smedj.2020159","article-title":"Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on in-hospital mortality in COVID-19 patients: a systematic review and meta-analysis","volume":"62","author":"Cai","year":"2021","journal-title":"Singapore Med J"},{"key":"10.1016\/j.repc.2022.02.014_bib0780","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/ehjcvp\/pvaa138","article-title":"Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes fromCoViD-19: systematic review and meta-analysis","volume":"8","author":"Lee","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.repc.2022.02.014_bib0785","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/thoraxjnl-2020-215322","article-title":"Renin-angiotensin system blocker and outcomes of COVID-19: a systematic review and meta-analysis","volume":"76","author":"Lee","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.repc.2022.02.014_bib0790","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/healthcare9020127","article-title":"Mortality, severity, and hospital admission among COVID-19 patients with ACEI\/ARB use: a meta-analysis stratifying countries based on response to the first wave of the pandemic","volume":"9","author":"Alamer","year":"2021","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.repc.2022.02.014_bib0795","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s43044-021-00135-y","article-title":"Clinical outcome of renin-angiotensin-aldosterone system blockers in treatment of hypertensive patients with COVID-19: a systematic review and meta-analysis","volume":"73","author":"Laurentius","year":"2021","journal-title":"Egypt Heart J"},{"key":"10.1016\/j.repc.2022.02.014_bib0800","first-page":"e13124","article-title":"Renin-angiotensin-aldosterone system inhibitors and COVID-19: a meta-analysis and systematic review","volume":"13","author":"Hassib","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.repc.2022.02.014_bib0805","doi-asserted-by":"crossref","first-page":"e213594","DOI":"10.1001\/jamanetworkopen.2021.3594","article-title":"Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis","volume":"4","author":"Baral","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.repc.2022.02.014_bib0810","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1038\/s41598-021-84678-9","article-title":"Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: meta-analysis","volume":"11","author":"Biswas","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.repc.2022.02.014_bib0815","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.cjco.2021.03.001","article-title":"Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors in COVID-19: meta-analysis\/meta-regression adjusted for confounding factors","volume":"3","author":"Lee","year":"2021","journal-title":"CJC Open"},{"key":"10.1016\/j.repc.2022.02.014_bib0820","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.18632\/aging.202902","article-title":"Does taking an angiotensin inhibitor increase the risk for COVID-19? A systematic review and meta-analysis","volume":"13","author":"Ma","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.repc.2022.02.014_bib0825","doi-asserted-by":"crossref","first-page":"609857","DOI":"10.3389\/fcvm.2021.609857","article-title":"Associations between the use of renin-angiotensin system inhibitors and the risks of severe COVID-19 and mortality in COVID-19 patients with hypertension: a meta-analysis of observational studies","volume":"8","author":"Dai","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.repc.2022.02.014_bib0830","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.medcli.2021.04.005","article-title":"Chronic use of renin-angiotensin-aldosterone inhibitors in hypertensive COVID-19 patients: results from a Spanish registry and meta-analysis","volume":"158","author":"Aparisi","year":"2022","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.repc.2022.02.014_bib0835","doi-asserted-by":"crossref","DOI":"10.1177\/20420986211011345","article-title":"Renin-angiotensin-aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis","volume":"12","author":"Kaur","year":"2021","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.repc.2022.02.014_bib0840","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41440-021-00670-w","article-title":"Renin-angiotensin system inhibitor use and the risk of mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials","volume":"44","author":"Kow","year":"2021","journal-title":"Hypertens Res"},{"key":"10.1016\/j.repc.2022.02.014_bib0845","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40292-021-00462-w","article-title":"Safety and efficacy of renin-angiotensin-aldosterone system inhibitors in COVID-19 population","volume":"28","author":"Sattar","year":"2021","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"10.1016\/j.repc.2022.02.014_bib0850","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1111\/bcp.14927","article-title":"Cardiovascular drugs and COVID-19 clinical outcomes: a living systematic review and meta-analysis","volume":"87","author":"Asiimwe","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.repc.2022.02.014_bib0855","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1111\/jch.14329","article-title":"Influence of angiotensin converting enzyme inhibitors\/angiotensin receptor blockers on the risk of all-cause mortality and other clinical outcomes in patients with confirmed COVID-19: a systemic review and meta-analysis","volume":"23","author":"Jia","year":"2021","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.repc.2022.02.014_bib0860","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13643-021-01802-6","article-title":"Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality","volume":"10","author":"Fernando","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.repc.2022.02.014_bib0865","series-title":"Position statement of the ESC council on hypertension on ACE-inhibitors and angiotensin receptor blockers","author":"European Society of Cardiology","year":"2020"},{"key":"10.1016\/j.repc.2022.02.014_bib0870","doi-asserted-by":"crossref","first-page":"5517441","DOI":"10.1155\/2021\/5517441","article-title":"The effect of chronic and inhospital exposure to renin-angiotensin system inhibitors on the outcome and inflammatory state of coronavirus disease 2019 adult inpatients","volume":"2021","author":"Gaspar","year":"2021","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.repc.2022.02.014_bib0875","doi-asserted-by":"crossref","first-page":"e00127-20","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.repc.2022.02.014_bib0880","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.repc.2022.02.014_bib0885","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.repc.2022.02.014_bib0890","doi-asserted-by":"crossref","first-page":"7988","DOI":"10.1073\/pnas.0409465102","article-title":"Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry","volume":"102","author":"Hofmann","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.repc.2022.02.014_bib0895","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1021\/acs.jpclett.0c01064","article-title":"Comparing the binding interactions in the receptor binding domains of SARS-CoV-2 and SARS-CoV","volume":"11","author":"Amin","year":"2020","journal-title":"J Phys Chem Lett"},{"key":"10.1016\/j.repc.2022.02.014_bib0900","series-title":"Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.repc.2022.02.014_bib0905","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-12-0341","article-title":"Angiotensin-converting enzyme 2, angiotensin-(1\u20137) and Mas: new players of the renin-angiotensin system","volume":"216","author":"Santos","year":"2013","journal-title":"J Endocrinol"},{"key":"10.1016\/j.repc.2022.02.014_bib0910","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","article-title":"Counter-regulatory renin-angiotensin system in cardiovascular disease","volume":"17","author":"Paz Ocaranza","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.repc.2022.02.014_bib0915","doi-asserted-by":"crossref","first-page":"14838","DOI":"10.1074\/jbc.M200581200","article-title":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase","volume":"277","author":"Vickers","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.repc.2022.02.014_bib0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.repc.2022.02.014_bib0925","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.1128\/JVI.01542-10","article-title":"Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2","volume":"84","author":"Matsuyama","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.repc.2022.02.014_bib0930","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/cr.2008.15","article-title":"SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res"},{"key":"10.1016\/j.repc.2022.02.014_bib0935","doi-asserted-by":"crossref","first-page":"e01933-17","DOI":"10.1128\/JVI.01933-17","article-title":"Entry of human coronavirus NL63 into the cell","volume":"92","author":"Milewska","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.repc.2022.02.014_bib0940","doi-asserted-by":"crossref","first-page":"100306","DOI":"10.1016\/j.jbc.2021.100306","article-title":"SARS-CoV-2 infects cells following viral entry via clathrin-mediated endocytosis","volume":"296","author":"Bayati","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.repc.2022.02.014_bib0945","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.repc.2022.02.014_bib0950","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/01.RES.26.5.591","article-title":"In-vivo and in-vitro conversion of angiotensin I to angiotensin II in dog blood","volume":"26","author":"Oparil","year":"1970","journal-title":"Circ Res"},{"key":"10.1016\/j.repc.2022.02.014_bib0955","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2007.05.015","article-title":"Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century","volume":"30","author":"Rolain","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.repc.2022.02.014_bib0960","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.repc.2022.02.014_bib0965","doi-asserted-by":"crossref","first-page":"623","DOI":"10.7326\/M20-4207","article-title":"Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial","volume":"173","author":"Skipper","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.repc.2022.02.014_bib0970","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","article-title":"Effect of hydroxychloroquine in hospitalized patients with Covid-19","volume":"383","author":"Horby","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2022.02.014_bib0975","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.repc.2022.02.014_bib0980","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1038\/s41467-018-06215-z","article-title":"Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies","volume":"9","author":"Madelain","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.repc.2022.02.014_bib0985","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.repc.2022.02.014_bib0990","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.repc.2022.02.014_bib0995","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.repc.2022.02.014_bib1000","doi-asserted-by":"crossref","first-page":"JC63","DOI":"10.7326\/ACPJ202006160-063","article-title":"In COVID-19, adding lopinavir-ritonavir to usual care did not shorten time to clinical improvement","volume":"172","author":"Yang","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.repc.2022.02.014_bib1005","doi-asserted-by":"crossref","first-page":"JC4","DOI":"10.7326\/ACPJ202007210-005","article-title":"Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement","volume":"173","author":"Paladugu","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.repc.2022.02.014_bib1010","doi-asserted-by":"crossref","first-page":"173926","DOI":"10.1016\/j.ejphar.2021.173926","article-title":"Remdesivir for treatment of COVID-19: an updated systematic review and meta-analysis","volume":"897","author":"Rezagholizadeh","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.repc.2022.02.014_bib1015","doi-asserted-by":"crossref","first-page":"106272","DOI":"10.1016\/j.cct.2021.106272","article-title":"Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"101","author":"Al-Abdouh","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.repc.2022.02.014_bib1020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.amsu.2020.12.051","article-title":"Remdesivir therapy in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"62","author":"Reddy Vegivinti","year":"2021","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.repc.2022.02.014_bib1025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.7326\/M20-5752","article-title":"Remdesivir for adults with COVID-19: a living systematic review for American College of Physicians Practice Points","volume":"174","author":"Wilt","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.repc.2022.02.014_bib1030","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/M20-8148","article-title":"Major update: remdesivir for adults with COVID-19: a living systematic review and meta-analysis for the American College of Physicians Practice Points","volume":"174","author":"Kaka","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.repc.2022.02.014_bib1035","doi-asserted-by":"crossref","first-page":"105631","DOI":"10.1016\/j.ejps.2020.105631","article-title":"Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial","volume":"157","author":"Lou","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.repc.2022.02.014_bib1040","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.repc.2022.02.014_bib1045","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.chest.2020.10.009","article-title":"Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in COVID nineteen study","volume":"159","author":"Rajter","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.repc.2022.02.014_bib1050","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.repc.2022.02.014_bib1055","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.repc.2022.02.014_bib1060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.repc.2022.02.014_bib1065","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","article-title":"SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801","volume":"591","author":"Wahl","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.repc.2022.02.014_bib1070","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jiab361","article-title":"Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a hamster infection model","volume":"224","author":"Abdelnabi","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.repc.2022.02.014_bib1075","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2022.02.014_bib1080","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.repc.2022.02.014_bib1085","doi-asserted-by":"crossref","first-page":"n2713","DOI":"10.1136\/bmj.n2713","article-title":"Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.repc.2022.02.014_bib1090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.coviro.2021.04.006","article-title":"Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection","volume":"49","author":"Vandyck","year":"2021","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.repc.2022.02.014_bib1095","doi-asserted-by":"crossref","first-page":"128333","DOI":"10.1016\/j.bmcl.2021.128333","article-title":"Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors","volume":"50","author":"Ullrich","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.repc.2022.02.014_bib1100","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/07391102.2020.1819881","article-title":"Potential protease inhibitors and their combinations to block SARS-CoV-2","volume":"40","author":"Abhinand","year":"2022","journal-title":"J Biomol Struct Dyn"},{"issue":"Suppl. 1","key":"10.1016\/j.repc.2022.02.014_bib1105","article-title":"SARS: epidemiology","volume":"8","author":"Chan-Yeung","year":"2003","journal-title":"Respirology"},{"key":"10.1016\/j.repc.2022.02.014_bib1110","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.repc.2022.02.014_bib1115","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1152\/japplphysiol.00742.2020","article-title":"Functional pathophysiology of SARS-CoV-2 induced acute lung injury and clinical implications","volume":"130","author":"Habashi","year":"2021","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.repc.2022.02.014_bib1120","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19","volume":"383","author":"Ackermann","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2022.02.014_bib1125","doi-asserted-by":"crossref","first-page":"L325","DOI":"10.1152\/ajplung.00189.2020","article-title":"Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury","volume":"319","author":"Sarzani","year":"2020","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.repc.2022.02.014_bib1130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0034-5687(94)00117-I","article-title":"Chronic hypoxia impairs pulmonary venous smooth muscle contraction","volume":"100","author":"Zhao","year":"1995","journal-title":"Respir Physiol"},{"key":"10.1016\/j.repc.2022.02.014_bib1135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coph.2017.12.002","article-title":"Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases","volume":"40","author":"Tan","year":"2018","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.repc.2022.02.014_bib1140","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/SHK.0000000000000633","article-title":"Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease","volume":"46","author":"Jia","year":"2016","journal-title":"Shock"},{"key":"10.1016\/j.repc.2022.02.014_bib1145","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.cellsig.2014.06.011","article-title":"A century old renin-angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology","volume":"26","author":"Balakumar","year":"2014","journal-title":"Cell Signal"},{"key":"10.1016\/j.repc.2022.02.014_bib1150","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","article-title":"Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic","volume":"75","author":"Driggin","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2022.02.014_bib1155","doi-asserted-by":"crossref","first-page":"8609","DOI":"10.4081\/idr.2020.8609","article-title":"Acute myocarditis as the main clinical manifestation of SARS-CoV 2 infection","volume":"12","author":"Cuomo","year":"2020","journal-title":"Infect Dis Rep"},{"key":"10.1016\/j.repc.2022.02.014_bib1160","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.repc.2022.02.014_bib1165","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/CIRCRESAHA.120.317447","article-title":"The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications","volume":"127","author":"McFadyen","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.repc.2022.02.014_bib1170","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620938149","article-title":"COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation","volume":"26","author":"Miesbach","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.repc.2022.02.014_bib1175","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1586\/erc.10.161","article-title":"Angiotensin II tissue factor and the thrombotic paradox of hypertension","volume":"8","author":"Celi","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.repc.2022.02.014_bib1180","first-page":"419","article-title":"Prothrombotic effects of angiotensin","volume":"45","author":"Brown","year":"2000","journal-title":"Adv Intern Med"},{"key":"10.1016\/j.repc.2022.02.014_bib1185","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/jmv.26232","article-title":"The cytokine storm and COVID-19","volume":"93","author":"Hu","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.repc.2022.02.014_bib1190","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.repc.2022.02.014_bib1195","doi-asserted-by":"crossref","first-page":"102452","DOI":"10.1016\/j.jaut.2020.102452","article-title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?","volume":"111","author":"Liu","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.repc.2022.02.014_bib1200","doi-asserted-by":"crossref","first-page":"102537","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease","volume":"19","author":"McGonagle","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.repc.2022.02.014_bib1205","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1053\/ajkd.1998.v31.pm9428470","article-title":"Angiotensin II and gene expression in the kidney","volume":"31","author":"Klahr","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.repc.2022.02.014_bib1210","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/HYPERTENSIONAHA.107.102152","article-title":"Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy","volume":"51","author":"Sriramula","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.repc.2022.02.014_bib1215","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1523\/JNEUROSCI.5599-12.2013","article-title":"Angiotensin II modulates salty and sweet taste sensitivities","volume":"33","author":"Shigemura","year":"2013","journal-title":"J Neurosci"},{"key":"10.1016\/j.repc.2022.02.014_bib1220","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1469-185X.1996.tb01284.x","article-title":"The neuronal role of angiotensin II in thirst, sodium appetite, cognition and memory","volume":"71","author":"Mosimann","year":"1996","journal-title":"Biol Rev Camb Philos Soc"},{"key":"10.1016\/j.repc.2022.02.014_bib1225","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fnagi.2017.00129","article-title":"Brain renin-angiotensin system and microglial polarization: implications for aging and neurodegeneration","volume":"9","author":"Labandeira-Garcia","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.repc.2022.02.014_bib1230","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1093\/brain\/awaa240","article-title":"The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings","volume":"143","author":"Paterson","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.repc.2022.02.014_bib1235","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10072-020-04932-2","article-title":"COVID-19, de novo seizures, and epilepsy: a systematic review","volume":"42","author":"Asadi-Pooya","year":"2021","journal-title":"Neurol Sci"},{"key":"10.1016\/j.repc.2022.02.014_bib1240","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1755-5949.2008.00057.x","article-title":"Ang II and Ang IV: unraveling the mechanism of action on synaptic plasticity, memory, and epilepsy","volume":"14","author":"De Bundel","year":"2008","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.repc.2022.02.014_bib1245","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0006-8993(91)90812-A","article-title":"Angiotensin II blocks hippocampal long-term potentiation","volume":"567","author":"Denny","year":"1991","journal-title":"Brain Res"},{"key":"10.1016\/j.repc.2022.02.014_bib1250","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00246-017-1760-0","article-title":"The roles of genetic factors in kawasaki disease: a systematic review and meta-analysis of genetic association studies","volume":"39","author":"Xie","year":"2018","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.repc.2022.02.014_bib1255","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.repc.2022.02.014_bib1260","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.eclinm.2021.100962","article-title":"Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial","volume":"37","author":"Duarte","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.repc.2022.02.014_bib1265","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/1468-0009.12210","article-title":"The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses","volume":"94","author":"Ioannidis","year":"2016","journal-title":"Milbank Q"},{"key":"10.1016\/j.repc.2022.02.014_bib1270","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","article-title":"Evidence based medicine: what it is and what it isn\u2019t","volume":"312","author":"Sackett","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.repc.2022.02.014_bib1275","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0140-6736(16)31592-6","article-title":"Progress in evidence-based medicine: a quarter century on","volume":"390","author":"Djulbegovic","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.repc.2022.02.014_bib1280","unstructured":"WHO-Europe. Evidence-informed policy-making. Available from: https:\/\/www.euro.who.int\/en\/data-and-evidence\/evidence-informed-policy-making\/about-us [accessed 15.02.21]."}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255123001191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255123001191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:12:43Z","timestamp":1760109163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255123001191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":128,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0870255123001191"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2022.02.014","relation":{},"ISSN":["0870-2551"],"issn-type":[{"value":"0870-2551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2022.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}